WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for the second quarter ended June 30, 2012. Total revenue for the three months ended June 30, 2012 was $799,000, compared to $797,000 for the same period in the prior year. Revenue in both periods is primarily attributable to sales of our Inherent Health® brand of genetic tests sold through our Merchant Network and Channel Partner Agreement with Amway Global.
